GLAUCOTENSIL®

Stable ophthalmic solution for the reduction of increased intraocular pressure.

**Pharmacological characteristics**

**Indications:**
- Decreased myocardial contractility; in these patients, the inhibition by beta-adrenergic receptor blockade may not be desirable. In cases in which myocardial contractility is depressed by the use of beta-blocking agents (i.e. heart failure), other inotropic agents are required. (See Precautions and Adverse Reactions.)

**Contraindications:**
- Known hypersensitivity to any component of this product.
- Pregnancy: Category C. The drug should only be used during pregnancy if clearly needed.
- Children: Safety and efficacy of this product in children have not been established.

**Warnings and Precautions:**
- Telithromycin and quinidine, possibly because quinidine inhibits the metabolism of Telithromycin via P-450 cytochrome. (See Precautions and Adverse Reactions.)
- Iodinated contrast media: Do not use iodinated contrast media with this product due to the possibility of anaphylactic reactions. (See Precautions and Adverse Reactions.)
- Beta-adrenergic blocking agents: Use with caution in patients with significant cardiovascular diseases. (See Precautions and Adverse Reactions.)

**Pharmacological properties:**
- **Pharmacodynamics:**
  - TIMOLOL Maleate: A beta-blocker that is highly selective for beta-1 receptors. (See Precautions and Adverse Reactions.)
- **Pharmacokinetics:**
  - TIMOLOL Maleate: A beta-blocker that is highly selective for beta-1 receptors. (See Precautions and Adverse Reactions.)

**Adverse reactions associated with topical Pilocarpine treatment include:**
- Blurred vision due to miosis and accommodative insufficiency.
- Headache, asthenia/fatigue, chest pain.
- Increased signs and symptoms of myasthenia gravis, paresis, weakness.
- Vertigo, depression.
- Increased signs and symptoms of myasthenia gravis, paresis, weakness.

**Storage conditions:**
- Store below 30°C.
- Once reconstituted, exposed to the air for the first time, it should be used within 28 days.

**Keep drugs out of reach of children.**

**Additional information:**
- Telithromycin and quinidine, possibly because quinidine inhibits the metabolism of Telithromycin via P-450 cytochrome. (See Precautions and Adverse Reactions.)
- Iodinated contrast media: Do not use iodinated contrast media with this product due to the possibility of anaphylactic reactions. (See Precautions and Adverse Reactions.)
- Beta-adrenergic blocking agents: Use with caution in patients with significant cardiovascular diseases. (See Precautions and Adverse Reactions.)

**Guía de colores/Colours Guide**

**Technical Director:**

Dr. M. D. O. Martinez

**Manufactured by:**

LABORATORIOS PENTOPÉN S.C.

**Laboratorios Penopen, S.C.**

**Colores/Colors:**

Pantone Black C

**Teléfono/Dial:**

Mezquita 305, 105-7, Mexico DF, Mexico

**Correo electrónico/Email:**

info@penopen.com

**Derechos reservados/© Copyright:**

2023 Penopen, S.A. de C.V.